Lipocine Inc. Q2 2026: Revenue $190099 EPS $(0.32) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Lipocine Inc. reported Q2 2026 results with revenue of $190,099, a 69.5% decline year-over-year, and a net loss of $(2.62) million. Diluted EPS was $(0.32). Revenue dropped due to lower licensing income, though TLANDO royalty revenue increased. The company executed major TLANDO licenses with Verity, SPC, Pharmalink, and Aché. Clinically, LPCN 1154 Phase 3 missed its primary endpoint, but post-hoc analysis showed potential efficacy. Capital raised via ATM supports operations through mid-2027.
Lipocine Inc. reported results for the quarter ended Q2 2026, with revenue of $190099 and a net loss attributable to common shareholders of $(2,622,595). Diluted loss per share was $(0.32), and revenue declined sharply versus the year‑ago quarter on lower licensing and other revenue mix.
Financial Highlights
- Revenue: $190,099 for Q2 2026, down from $622,849 in Q2 2025 ( (69.5%) ).
- Net income: Net loss attributable to common shareholders of $(2,622,595) for Q2 2026, versus $(2,205,716) in Q2 2025 (worse YoY).
- Diluted EPS: $(0.32) for Q2 2026, compared with $(0.41) in Q2 2025.
Business Highlights
- Revenue mix shifted toward royalty revenue from TLANDO; licensing revenue was down versus the prior year, affecting near‑term top‑line composition.
- Clinical update: LPCN 1154 Phase 3 topline missed its primary endpoint; a post‑hoc analysis excluding one outlier site indicated potential efficacy.
- Partnerships and licensing: Executed major TLANDO licenses with Verity, SPC, Pharmalink and Aché, creating a pipeline of milestones, royalties and commercial support.
- Pipeline progress: Multiple programs across CNS, liver, obesity and maternal health advanced with Phase 1–3 activity, IND/PK studies and planned trials.
- Liquidity: Capital raised via an ATM in 2026 increased cash resources to support operations and near‑term clinical activities through mid‑2027.
Original SEC Filing: Lipocine Inc. [ LPCN ] - 10-Q - Aug. 04, 2026